Background: The literature reports conflicting results regarding the effect of human papillomavirus (HPV)-16/18 positivity on cervical cancer (CC) prognosis. Aim: To conduct a meta-analysis to examine the effect of HPV-16/18 positivity on the prognosis of patients with CC. Methods: PubMed, Embase, and the Cochrane library were searched for available papers published up to March 2020. The main outcome was the hazard ratio (HR) of overall survival (OS) or disease-free survival (DFS) comparing HPV-16 or HPV-18 positivity and negativity. And the random-effects model was used for synthesizing survival outcomes. Results: Nine studies and 2028 patients were included. Four studies reported OS in HPV-16 positivity, and no association was found between HPV-16 positivity and OS to CC (HR=0.79, 95%CI: 0.26-2.39, P=0.675). Three studies reported DFS in HPV-16 positivity, and no association was found between HPV-16 positivity and DFS to CC (HR=0.80, 95%CI: 0.30-2.11, P=0.654). Two studies reported DFS in HPV-18 positivity, and no association was found between HPV-18 positivity and DFS to CC (HR=0.99, 95%CI: 0.55-1.78, P=0.984). One study reported progression-free survival (PFS) in HPV-18 positivity, and an association was observed between HPV-18 positivity and PFS to CC (HR=2.66, 95%CI: 1.44-4.94, P=0.002). The sensitivity analyses showed that one study biased the analysis of the association between HPV-16 and OS, and another study biased the association between HPV-16 and DFS. Conclusion: The presence of HPV-16 and HPV-18 positivity had no significant association with prognosis in CC in either OS or PFS.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: